Provided by Tiger Fintech (Singapore) Pte. Ltd.

California Resources

43.16
-0.6200-1.42%
Post-market: 43.14-0.0200-0.05%16:10 EDT
Volume:549.25K
Turnover:23.55M
Market Cap:3.85B
PE:7.50
High:43.17
Open:42.74
Low:42.22
Close:43.78
Loading ...

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

GlobeNewswire
·
03 Mar

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
03 Mar

California Resources Corporation's (NYSE:CRC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Simply Wall St.
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Nasdaq Jumps 300 Points As Nvidia, Tesla Stocks Surge: Investor Sentiment Improves, But Greed Index Remains In 'Extreme Fear' Zone

Benzinga
·
03 Mar

California Resources, Okta And 3 Stocks To Watch Heading Into Monday

Benzinga
·
03 Mar

Ahead of California Resources (CRC) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks
·
27 Feb

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

Business Wire
·
27 Feb

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

GlobeNewswire
·
27 Feb

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
27 Feb

Talos Energy (TALO) Q4 Earnings Surpass Estimates

Zacks
·
27 Feb

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Business Wire
·
27 Feb

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire
·
27 Feb

CRC or RRC: Which Is the Better Value Stock Right Now?

Zacks
·
27 Feb

Riley Exploration Permian, Inc. (REPX) Reports Next Week: Wall Street Expects Earnings Growth

Zacks
·
26 Feb

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Business Wire
·
25 Feb

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...

Business Wire
·
24 Feb

Guardant Health: Positioned for Growth with Shield CRC and Strategic Market Advantages

TIPRANKS
·
23 Feb

California Resources announces partial redemption of senior notes

TIPRANKS
·
18 Feb

BRIEF-California Resources Corporation Announces Partial Redemption Of 7.125% Senior Notes Due 2026

Reuters
·
18 Feb